The PE ratio for Champions Oncology stock stands at 16.81 as of Apr 25, 2025. This takes into account the latest EPS of $0.47 and stock price of $7.9.
Over the last six years, the average PE ratio of Champions Oncology has been 470.6. The current 16.81 P/E ratio is 96% lower than the historical average. Looking back at the last six years, CSBR's PE ratio peaked in the Jul 2021 quarter at 1,045, with a price of $10.45 and an EPS of $0.01. The Jan 2025 quarter marked the lowest point at 23.38, with a price of $10.99 and an EPS of $0.47.
Maximum annual decrease: -46.32% in 2022
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $4.85 | -$0.54 |
2023 | N/A | N/A | $4.92 | -$0.39 |
2022 | 192 | -46.32% | $7.68 | $0.04 |
2021 | 357.67 | N/A | $10.73 | $0.03 |
2020 | N/A | N/A | $7.72 | -$0.18 |
2019 | 908 | N/A | $9.08 | $0.01 |
2018 | N/A | N/A | $4.34 | -$0.13 |
2017 | N/A | N/A | $2.65 | -$0.64 |
2016 | N/A | N/A | $3.85 | -$1.2 |
2015 | N/A | N/A | $7.32 | -$2.2 |
2014 | N/A | N/A | $10.92 | -$1.33 |
2013 | N/A | N/A | $5.28 | -$1.44 |
2012 | N/A | N/A | $8.04 | -$2.28 |
2011 | N/A | N/A | $12 | -$1.32 |
2010 | N/A | N/A | $9.24 | -$1.08 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Jan 2025 | 23.38 | N/A | $10.99 | $0.47 |
Oct 2024 | N/A | N/A | $3.91 | -$0.05 |
Jul 2024 | N/A | N/A | $4.79 | -$0.25 |
Apr 2024 | N/A | N/A | $4.85 | -$0.54 |
Jan 2024 | N/A | N/A | $5.81 | -$0.72 |
Oct 2023 | N/A | N/A | $5.46 | -$0.71 |
Jul 2023 | N/A | N/A | $6.5 | -$0.56 |
Apr 2023 | N/A | N/A | $4.92 | -$0.39 |
Jan 2023 | N/A | N/A | $4.11 | -$0.23 |
Oct 2022 | 694 | 140.41% | $6.94 | $0.01 |
Jul 2022 | 288.67 | 50.35% | $8.66 | $0.03 |
Apr 2022 | 192 | -52.12% | $7.68 | $0.04 |
Jan 2022 | 401 | 23.13% | $8.02 | $0.02 |
Oct 2021 | 325.67 | -68.84% | $9.77 | $0.03 |
Jul 2021 | 1,045 | 192.17% | $10.45 | $0.01 |
CSBR's current PE ratio is lower than its 5 and 10-year averages.
In comparison to its peer stocks EXEL and CRL, CSBR's PE ratio is lower.
Stock name | PE ratio | Market cap |
---|---|---|
CSBR Champions Oncology Inc | 16.81 | $109.23M |
EXEL Exelixis Inc | 20.79 | $10.48B |
CRL Charles River Laboratories International Inc | 573.3 | $5.86B |
CLDX Celldex Therapeutics Inc | N/A | $1.3B |
The price to earnings ratio for CSBR stock is 16.81 as of Apr 25, 2025.
The 5-year average price to earnings ratio for CSBR stock is 415.92.
The highest quarterly PE ratio in the last six years has been 1,045 and it was in the Jul 2021 quarter.
CSBR's price to earnings ratio is currently 96% below its 6-year historical average.
The P/E ratio is obtained by dividing the latest price of a stock by its trailing twelve months EPS. As of today (Apr 25, 2025), Champions Oncology's share price is $7.9. The company's earnings per share for the trailing twelve months (TTM) ending Jan 2025 is $0.47. Therefore, Champions Oncology's PE ratio for today is 16.81. PE RATIO(16.81) = STOCK PRICE($7.9) / TTM EPS($0.47)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.